Patent ID: 11969439
Assignee: EXELA PHARMA SCIENCES, LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 16:
17. A method of treating a subject having an adverse health condition that is responsive to L-cysteine administration, said method comprising:
parenterally administering to said subject a composition, the composition comprising:
a solution comprising L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof;
Aluminum; and,
a pharmaceutically acceptable carrier;
wherein the ratio of L-cysteine to Aluminum is from about 35,000,000 to about 140,000:1 for at least 12 months from the time of manufacture of the solution; and,
wherein the solution:
has a pH from about 1.0 to about 2.5;
is substantially free of visually detectable particulate matter; and,
the solution provides not more than 3 mcg/kg/day of aluminum.